Actavis introduces US generic specialty injectable portfolio

Actavis will immediately begin marketing approximately 20 injectable products across a number of therapeutic categories in the US.

The Company will be a leader in Oncology, with nearly a dozen marketed products including generic versions of Gemzar, Taxotere, Campostar and Zometa.

Actavis also has an industry leading specialty injectable pipeline, with approximately 20 new filings under review at the U.S. Food and Drug Administration (FDA), as well as more than 50 additional projects currently in development.

Many of Actavis’ generic specialty injectable products were previously marketed in the U.S. by Sagent Pharmaceuticals, Inc. under a manufacturing and supply agreement originally signed by the companies in 2010. Actavis regained U.S. marketing rights to the products following the expiration of the Sagent agreement on December 31, 2014.

"Over the last several years, we have been steadily growing our generic specialty injectable business around the world, marketing products in more than 50 countries," said Brent Saunders, CEO and President of Actavis.

"With the addition of this diverse portfolio of injectable products to our U.S. portfolio, we will create a leading specialty injectable business within Actavis and immediately become a strong competitor in this important, high-value space.

"In addition, we will continue to invest in the development of our industry-leading generic injectable pipeline as part of our strategy to drive growth through complex, high-barrier-to-entry products.

"With our proven, well-established supply chain, experience in hospital sales from our brand anti-infective portfolio and strong existing customer relationships, our specialty injectable business is positioned to be a strong growth driver for our Company going forward "